Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang
Tempest Therapeutics (TPST) signed an exclusive option agreement with China's Hebei Senlang Biotechnology to license a clinical-stage technology that delivers CAR-T cancer treatments directly inside the body, along with a portfolio of related drug candidates.The portfolio includes an early-stage treatment that targets two proteins linked to multiple myeloma and is now being tested in a phase 1 study, Tempest said Tuesday in a statement. Other candidates in the group are aimed at blood cancers and autoimmune diseases, the company said.Tempest said it will continue to evaluate phase 1 results with Senlang during the option period.The company also disclosed in a regulatory filing that it raised about $2.5 million last week through a private placement of prefunded and common stock warrants.Tempest shares rose 35% in after-hours trading.
